toxicities was high (92%), but mostly manageable without major complications. Fourteen patients received 3 g/m², 4 patients received 2 g/m², 7 patients received 1 g/m² of cytarabine, and the rate of grade 4 leukopenia/thrombocytopenia was 64% (7), 25% (6), and 29% (1), respectively.

DISCUSSION: HD-cytarabine consolidation therapy with dose modification according to age groups for PCNSL was feasible and well-tolerated in patients 80 years of age or younger. The efficacy of HD-cytarabine was underdetermined and further investigation is warranted.

ML-09
THE REAL-WORLD OF ELDERLY PCNSL THERAPY IN TOHOKU AND NIGATA AREA ACCORDING TO RETROSPECTIVE ANALYSIS: A COST-UTILITY STUDY OF THE TOHOKU BRAIN TUMOR STUDY GROUP
Kenichiro Asano1, Yiyo Yamashita1, Takahiro Ono1, Manabu Natsume1, Takeki Reppu1, Kenichiro Matsuda1, Masahiro Ikikawa1, Masayuki Kana1, Manabu Matsuoka1, Akira Kuri1, Kiyoji Saito1, Yukiho Sonoda1, Kuniaki Ogasawara1, Yukihiko Fujii1, Kuniaki Shimizu1, Hiroki Ohkuma1, Chifumi Kitahata1, Takamasa Kayama1, Teiji Tominaga1. 1Department of Neurosurgery, Hiroshi University Graduate School of Medicine, Hiroshi, Japan

INTRODUCTION: Recently, the number of cases of primary central nervous system lymphoma in elderly patients (EL-PCNSL) has been increasing. Furthermore, the treatment may be insufficient because of poor performance status and pre- and post-treatment complications. Therefore, we analyzed the risk factors for EL-PCNSL in the Tohoku and Niigata areas of Japan and clarified the REAL-WORLD of EL-PCNSL therapy.

MATERIALS & METHODS: We compared the clinical and nonclinical outcomes of age groups. Patients aged 71 years or older from eight facilities during the last 8 years. We analyzed patient information, radiotherapy/chemotherapy, or not, OS, ORRs, second-line therapy, pre- and post-treatment complications, outcomes, and risk factors for poor prognosis. The log-rank test was used for univariate analysis, and Cox regression analysis was used for a multivariate analysis of risk factors.

RESULTS: Of the 142 cases registered, five different from PCNSL pathologically, three receiving BSC were excluded, 31 were treated without biopsy, three were treated based on CSF-finding, and 100 were treated with biopsy. Total 134 cases were followed. The median age was 76 years, pre-treatment PTX was 50%, and 118 cases (88%) had 217 pretreatment complications. The treatment contents consisted of various combinations depending on the attending physician. The retrospective overall survival (OS) was 16 months and 24 months. In the early treatment groups, 40% recurred and 30% died from 14 to 14.0 months, respectively. CR rate was 78% and two patients were not achieved CR due to the adverse events (AEs) which were acute tubular nephrosis and pneumocystis pneumonia. But meanwhile, there was no AE by MT. Median OS, median time of radiation free period and delayed neural toxicity was 19.5 months (95% CI 3-3), 5.0 months (95% CI 2-22), 2.5 months, and 8.2 months, respectively.

DISCUSSION: The results of this study might be inferior to other reports of elderly patients due to poor median KPS. And low introduction rate of RT was undesirable. However, once MT was introduced, MT itself was safe and easy to manage and the long-term prognosis was relatively excellent.

CONCLUSION: Rechallenge of HD-MTX and maintenance therapy of MTX might be promising but the problems of some serious AEs and low CR rate with HD-MTX alone should be resolved.

ML-14
RE-CHALLENGE AND MAINTENANCE THERAPY OF METHOTREXATE FOR ELDERLY PCNSL PATIENTS WITH LOW SCORES
Takashi Yamaguchi, Rie Nagayama, Akira Gomi, Kenseku Kawazaki
1Department of Neurosurgery, Jichi Medical University, Shimotsuke, Japan

PURPOSE: The delayed neuronal toxicity after high dose methotrexate (HD-MTX) followed by radiotherapy (RT) is a serious problem for elderly primary CNS lymphoma patients. We started maintenance therapy (MT) with MTX after achieving complete remission (CR) to defer RT for elderly and poor Karnofsky Performance Scale (KPS) patients.

METHODS: We performed HD-MTX (3 g/m²) therapy until achieving CR for the patients over 70 years whose KPS were equal to or less than 60%. After having CR, 3 courses of MTX (3 g/patient) for 3 weeks were introduced every 3–4 months for 2 years. At the time of recurrence, HD-MTX was repeated. But when CR was not achieved by HD-MTX alone, RT was introduced. Moreover, additional use of rituximab was considered if patients’ condition became better.

RESULTS: Number of patients was 9. Median age, median KPS, and median follow-up periods were 75 yo (71–78), 40% (30–60), and 14.0 months (1–55), respectively. CR rate was 78% and two patients were not achieved CR due to the adverse events (AEs) which were acute tubular nephrosis and pneumocystis pneumonia. But meanwhile, there was no AE by MT. Median OS, median time of radiation free period and delayed neural toxicity was 19.5 months (95% CI 3-3), 5.0 months (95% CI 2-22), 2.5 months, and 8.2 months, respectively.

DISCUSSION: The results of this study might be inferior to other reports of elderly patients due to poor median KPS. And low introduction rate of MT was undesirable. However, once MT was introduced, MT itself was safe and easy to manage and the long-term prognosis was relatively excellent.

CONCLUSION: Rechallenge of HD-MTX and maintenance therapy of MTX might be promising but the problems of some serious AEs and low CR rate with HD-MTX alone should be resolved.

ML-15
THE FUTURE DIRECTION OF TREATMENT DEVELOPMENT FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Narihira Takahiro1, Kenji Fujimoto2, Takahiro Yamanaka1, Kota Kato1, Tatsuya Takezaki1, Jun-ichiro Sayama1, Keishi Makino2, Akita Mukasa2
1Department of Neurosurgery, Kumamoto University Hospital, Kumamoto, Japan

PURPOSE: We found that the combination of high-dose Methotrexate (HD-MTX)-based therapy and histone deacetylase inhibitor (HDACI) had a therapeutic effect on PCNSL. In addition, this year, tirabrutinib, a Bruton’s tyrosine kinase inhibitor, was approved for marketing as a single agent for relapsed/refractory PCNSL, and new therapeutic development is expected. We will examine the treatment results of PCNSL in our department retrospectively and discuss the future direction of treatment development. METHODS: From 2001 to 2014, 82 newly diagnosed PCNSL patients treated with HD-MTX/PCarbazine (MP) as initial remission induction chemotherapy were retrospectively analyzed. RESULTS: Complete response (CR) was obtained in 38 patients (46.3%) after initial chemotherapy, and the median overall survival (OS) in the CR and non-CR groups was 2636 days and 728 days, respectively, and significantly shorter in the non-CR group (p<0.01). In the CR group, 27 cases (71.1%) recurred and 12 cases received HD-MTX re-challenge (M-re), 14 cases received treatment other than M-re (1 case did not receive treatment), the median OS after relapse was 590 days. The median post-relapse progression-free survival (PFS) of the 10 patients undergoing M-re at the first relapse was 116 days, the median OS after relapse was 590 days. The median post-relapse PFS of 16 patients receiving other treatments was 388 days, the median OS after relapse was 532 days. There was no difference in PFS and OS after recurrence in treatment at the first recurrence (p=0.15, p=0.55). CONCLUSION: The OS of non-CR patients in the initial chemotherapy and the OS after recurrence after CR were short. The possible directions of PCNSL treatment development include 1) increasing the CR rate with initial chemotherapy and maintaining CR for a long time for newly diagnosed PCNSL, and 2) finding an effective treatment for recurrence. New drugs such as tirabrutinib and HDACIs may be breakthroughs.